INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.75

23 Sep
2021

0.020

OPEN

$4.80

0.42%

HIGH

$4.84

618,538

LOW

$4.72

TARGET
$5.08 6.9% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx 15.8 18.5 xxx
DPS (cps) xxx 12.5 12.3 xxx
EPS Growth xxx 27.1% 16.9% xxx
DPS Growth xxx 31.6% - 1.7% xxx
PE Ratio xxx N/A 25.6 xxx
Dividend Yield xxx N/A 2.6% xxx
Div Pay Ratio(%) xxx 79.1% 66.5% xxx

Dividend yield today if purchased 3 years ago: 4.73%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

2.64

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 02/09 - 7c (0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx15.8
DPS All xxxxxxxxxxxxxxx12.5
Sales/Revenue xxxxxxxxxxxxxxx348.8 M
Book Value Per Share xxxxxxxxxxxxxxx128.2
Net Operating Cash Flow xxxxxxxxxxxxxxx69.6 M
Net Profit Margin xxxxxxxxxxxxxxx8.96 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Assets xxxxxxxxxxxxxxx5.06 %
Return on Equity xxxxxxxxxxxxxxx12.95 %
Return on Total Capital xxxxxxxxxxxxxxx8.95 %
Capex xxxxxxxxxxxxxxx20.3 M
Capex % of Sales xxxxxxxxxxxxxxx5.81 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx31.4 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Credit Suisse

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

31/08/2021

2

Accumulate

$5.05

6.32%

Integral Diagnostics delivered FY21 revenue in-line with Ord Minnett's forecast though elevated opex resulted in a -4% and -3% miss for earnings (EBITDA) and profit. The broker retains its Accumulate rating, given durable earnings and the long-term growth profile.

The analyst points out there is now a trade-off between nearer-term EPS accretion from bolt-on acquisitions and mid-term earnings benefits. This is because suitable M&A opportunities are becoming harder to come by and greenfield opportunities are being scoured.

The target price is adjusted to $5.05 from $5.09.

FORECAST
Ord Minnett forecasts a full year FY22 dividend of 12.00 cents and EPS of 16.70 cents.
Ord Minnett forecasts a full year FY23 dividend of 13.00 cents and EPS of 21.60 cents.

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

(xx/xx/xxxx)

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

IDX STOCK CHART